We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -36.00 | -0.30% | 12,120.00 | 12,118.00 | 12,122.00 | 12,130.00 | 12,010.00 | 12,092.00 | 326,749 | 12:00:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.35 | 186.7B |
From May 2021 to May 2024
By Michael Dabaie
F-star Therapeutics Inc. said it is in an exclusive licensing agreement with AstraZeneca PLC, sending shares higher premarket.
AstraZeneca will receive global rights to research, develop and commercialize next generation Stimulator of Interferon Genes, or STING, inhibitor compounds. F-star is a clinical-stage biopharmaceutical company focused on bispecific immunotherapies for cancer.
AstraZeneca will be responsible for all future research, development and commercialization of the STING inhibitor compounds, and F-star will retain rights to all STING agonists, currently in clinical development for patients with cancer.
F-star is eligible to receive upfront and near-term payments of up to $12 million. F-star can also receive development and sales milestone payments of more than $300 million, as well as single digit percentage royalty payments.
F-star shares were up 8% to $7.95 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 08, 2021 08:43 ET (12:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
